ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
A Photothermally Triggered Cascade Nanodelivery Platform for On-Demand Nitric Oxide Release in Targeted Hepatocellular Carcinoma Therapy.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Traditional nanoparticle delivery systems for hepatocellular carcinoma (HCC) rely on passive targeting and low drug release rates, limiting efficacy, while the biocompatible nitric oxide (NO) donor L-Arginine (L-Arg) is prone to systemic leakage, hindering precise HCC delivery. In the content, we constructed a cascade-responsive nanoplatform based on porous hollow gold nanocages (GNCs) that integrates spatial targeting and temporal activation of multimodal treatment. By co-loading the near-infrared (NIR) photosensitizer indocyanine green (ICG) and the NO precursor L-Arg into GNCs, and conjugating the HCC-targeting peptide 9R-P201 on the surface, we obtained the multifunctional nanoplatform GIL9R. Upon NIR irradiation, GIL9R nanoplatform simultaneously generated localized hyperthermia (photothermal therapy, PTT) and the resulting strong oxidizing agent. The resulting reactive oxygen species (ROS) catalyze L-Arg oxidation via an enzyme-mimetic pathway to produce NO, triggering gas therapy (GT) in situ. This PTT/PDT-initiated NO release synchronizes three modalities, yielding potent synergistic cytotoxicity against HCC cells. In vitro, GIL9R nanoplatform showed high HCC affinity, effective photodynamic therapy (PDT), and robust NO-mediated GT. In vivo, GIL9R nanoplatform selectively accumulated in tumors and significantly suppressed tumor growth. This rationally designed cascade platform leverages intrinsic synergy among PTT, PDT, and GT, offering a translatable strategy for precision liver cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.